Edmond DE Rothschild Holding S.A. Takes Position in Moderna, Inc. $MRNA

Edmond DE Rothschild Holding S.A. acquired a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 70,747 shares of the company's stock, valued at approximately $4,954,000.

Other hedge funds have also recently bought and sold shares of the company. Shepherd Financial Partners LLC acquired a new stake in shares of Moderna in the second quarter worth about $215,000. Mmbg Investment Advisors CO. bought a new stake in shares of Moderna during the 2nd quarter worth about $200,000. Danske Bank A S acquired a new position in shares of Moderna during the 2nd quarter valued at about $165,000. Wealthfront Advisers LLC acquired a new position in shares of Moderna during the 2nd quarter valued at about $1,094,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new position in shares of Moderna in the 2nd quarter valued at approximately $49,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MRNA shares. Morgan Stanley restated a "neutral" rating on shares of Moderna in a report on Wednesday. William Blair raised shares of Moderna from a "market perform" rating to an "outperform" rating in a research report on Wednesday. Brookline Capital Markets reissued a "buy" rating on shares of Moderna in a research report on Wednesday. Citigroup boosted their price objective on shares of Moderna from $41.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. Finally, Bank of America raised shares of Moderna from an "underperform" rating to a "neutral" rating in a report on Wednesday. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, Moderna has a consensus rating of "Hold" and an average price target of $56.56.

Moderna Stock Up 177.0%

Shares of MRNA opened at $174.38 on Thursday. The company has a 50-day simple moving average of $64.91 and a 200-day simple moving average of $54.84. The firm has a market capitalization of $69.62 billion, a P/E ratio of -21.82 and a beta of 0.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.13) earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -6.18 earnings per share for the current year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma trial met both key endpoints. Intismeran, Moderna’s individualized mRNA neoantigen therapy, combined with Merck’s Keytruda, significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with resected, high-risk melanoma. The companies described the results as the first positive late-stage trial for a personalized mRNA cancer vaccine. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: The results support a broader cancer-treatment opportunity. Analysts and medical commentators said the outcome could validate Moderna’s mRNA platform for treating cancer and potentially open development opportunities across additional tumor types. The vaccine is tailored to mutations in an individual patient’s tumor, offering a potentially differentiated approach to personalized oncology. Moderna and Merck cancer vaccine breakthrough
• Positive Sentiment: Additional developments added to the bullish sentiment. The FDA approved Moderna’s first mRNA-based seasonal influenza vaccine, mFLUSIVA, while William Blair upgraded the stock to “outperform” and Bank of America moved its rating from “underperform” to “neutral.” FDA approval of Moderna mFLUSIVA
• Neutral Sentiment: Investors are awaiting detailed trial data. Moderna and Merck released topline results, but analysts said full efficacy, safety and durability data will be important for assessing regulatory timing and the vaccine’s commercial potential.
• Negative Sentiment: The sharp rally raises execution and valuation risks. The move triggered substantial losses for short sellers and increased options activity, while the stock now reflects much higher expectations for successful approval, manufacturing and adoption. Any disappointing detailed data or regulatory delays could lead to volatility.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source